clazakizumab

Home
Ligands
clazakizumab

GtoPdb Ligand ID: 9195

Synonyms: ALD-518 | ALD518 | BMS-945429

Comment: Clazakizumab is an investigational, aglycosylated, humanized (from a rabbit parental antibody) monoclonal antibody targeting interleukin-6, with anti-inflammatory potential [2].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. BLAST peptide sequence analysis reveals identical matches with peptides claimed in patent US8062864 [3]. Results presented in the patent show that the preferred antibodies block interaction of IL-6 with the IL-6 receptor, but no precise binding affinity data is provided.

No information available.

No information available.

Summary of Clinical Use
Phase 2 clinical trials in patients with active rheumatoid arthritis (NCT01373151, results reported in [6]), psoriatic arthritis (NCT01490450, results in [5]), cachexia resulting from non-small cell lung cancer [1,4], acute graft versus host disease (GvHD) and oral mucositis caused by head and neck cancer have been completed. Click here to link to ClinicalTrials.gov's list of clazakizumab (ALD518 and BMS-945429) trials. SARS-CoV-2 and COVID-19: Clazakizumab has been entered into clinical trials in patients with COVID-19, with a particular focus on assessing its efficacy in those with life-threatening hyperinflammation.

Summary of Clinical Use

Phase 2 clinical trials in patients with active rheumatoid arthritis (NCT01373151, results reported in [6]), psoriatic arthritis (NCT01490450, results in [5]), cachexia resulting from non-small cell lung cancer [1,4], acute graft versus host disease (GvHD) and oral mucositis caused by head and neck cancer have been completed. Click here to link to ClinicalTrials.gov's list of clazakizumab (ALD518 and BMS-945429) trials.

SARS-CoV-2 and COVID-19: Clazakizumab has been entered into clinical trials in patients with COVID-19, with a particular focus on assessing its efficacy in those with life-threatening hyperinflammation.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT01373151	Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate	Phase 2 Interventional	Vitaeris INC
NCT01490450	Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy	Phase 2 Interventional	Vitaeris INC
NCT04381052	Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection	Phase 2 Interventional	Columbia University
NCT04363502	Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection	Phase 2 Interventional	Johns Hopkins University
NCT04351724	Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)	Phase 2/Phase 3 Interventional	Medical University of Vienna
NCT04348500	Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease	Phase 2 Interventional	Cedars-Sinai Medical Center
NCT04343989	A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection	Phase 2 Interventional	NYU Langone Health